ダウンロード数: 176

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
j.nucmedbio.2019.08.001.pdf741.25 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorYagi, Yusukeen
dc.contributor.authorKimura, Hiroyukien
dc.contributor.authorOkuda, Harukaen
dc.contributor.authorOno, Masahiroen
dc.contributor.authorNakamoto, Yujien
dc.contributor.authorTogashi, Kaorien
dc.contributor.authorSaji, Hideoen
dc.contributor.alternative屋木, 祐亮ja
dc.contributor.alternative木村, 寛之ja
dc.contributor.alternative小野, 正博 /中本, 裕士ja
dc.contributor.alternative富樫, かおりja
dc.contributor.alternative佐治, 英郎ja
dc.date.accessioned2019-09-10T02:10:34Z-
dc.date.available2019-09-10T02:10:34Z-
dc.date.issued2019-07-
dc.identifier.issn0969-8051-
dc.identifier.issn1872-9614-
dc.identifier.urihttp://hdl.handle.net/2433/243897-
dc.description.abstractIntroduction: To understand the pathways involved in drug clearance from the body, quantitative evaluations of the hepatobiliary transport of drugs are important. The organic anion transporting polypeptide (OATP) family transporter, particularly OATP1B1 and 1B3, are considered to play an important role in hepatic uptake of organic anion compounds. Pitavastatin is a substrate of OATP, and it includes a fluorine group. Therefore, it represents an acceptable positron-emission tomography (PET) tracer using fluorine-18 to image in vivo hepatic transporter functions. Method: [¹⁸F]Pitavastatin was synthesized using the method we previously reported. To evaluate the potential of [¹⁸F]pitavastatin in PET imaging of in vivo OATP functions, we investigated the hepatic uptake with/without rifampicin as an OATP inhibitor after administration in normal SD rats. [¹⁸F]Pitavastatin metabolite was evaluated using reverse-phase thin-layer chromatography (TLC) autoradiography. We subsequently analyzed the PET image results and demonstrated that [¹⁸F]pitavastatin selectively accumulated in the liver post-administration. Result and discussion: In metabolite analysis using reverse-phase TLC, we found that the radioactivity detected in the plasma, liver (>90% intact), and bile mostly originated from the parent pitavastatin of the PET study (~40 min). [¹⁸F]pitavastatin's hepatic uptake decreased (approximately 76%) with rifampicin co-administration in PET analysis. Because [¹⁸F]pitavastatin has lower clearance in rats than other previously reported OATP1B PET s, it holds the potential of an imaging tracer that has a higher sensitivity in monitoring hepatic OATP1B function's changes. Conclusion: Compared with the previously reported OATP imaging tracers, [¹⁸F]pitavastatin is more suitable for the sensitive detection of functional changes in OATP transporters. We believe that [¹⁸F]pitavastatin enables quantitative analysis of the hepatobiliary transport system for organic anion compounds.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier Inc.en
dc.rights© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.en
dc.rightsThe full-text file will be made open to the public on 1 July 2020 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.en
dc.rightsこの論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。ja
dc.rightsThis is not the published version. Please cite only the published version.en
dc.subjectOrganic anion transporting polypeptideen
dc.subjectPositron-emission tomographyen
dc.subjectFluorine-18en
dc.subjectPitavastatinen
dc.subjectIntegration plot methoden
dc.titleEvaluation of [¹⁸F]pitavastatin as a positron emission tomography tracer for in vivo organic transporter polypeptide functionen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleNuclear Medicine and Biology-
dc.identifier.volume74-75-
dc.identifier.spage25-
dc.identifier.epage31-
dc.relation.doi10.1016/j.nucmedbio.2019.08.001-
dc.textversionauthor-
dc.addressDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University・Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical Universityen
dc.addressDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University・Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical Universityen
dc.addressDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto Universityen
dc.addressDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto Universityen
dc.addressDepartment of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto Universityen
dc.identifier.pmid31450072-
dcterms.accessRightsopen access-
datacite.date.available2020-07-01-
datacite.awardNumberJP25713046-
datacite.awardNumberJP17K10377-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName日本学術振興会ja
jpcoar.funderName.alternativeJapan Society for the Promotion of Science (JSPS)en
jpcoar.funderName.alternativeJapan Society for the Promotion of Science (JSPS)en
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。